FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2126299285> ?p ?o ?g. }

• W2126299285 endingPage "326" @default.
• W2126299285 startingPage "326" @default.
• W2126299285 abstract "Chronic spontaneous urticaria is defined as persistent symptoms of urticaria for 6 weeks or more. It is associated with autoimmunity in approximately 45 percent of patients. Therapy is often difficult however the initial approach should employ high-dose non-sedating antihistamines; 4-6 tablets/day may be necessary. It has been shown that the response to 4 tablets/day exceeds 3, and exceeds 2, which exceeds 1. However the dose that corresponds to the maximal dose of first generation antihistamines (hydroxyzine, diphenhydramine) used previously, is 6/day. Yet over half the patients are refractory to antihistamines and other agents should be tried next. Whereas current guidelines (published) often add leukotriene antagonists and/or H(2) receptor antogonists next, these are of little utility. Likewise drugs effective for urticarial vasculitis (colchicine, dapsone, sulfasalazine, hydroxychloroquine) are effective in a small percentage of patients and no study suggests that the response rate of any of them exceeds the 30% placebo responses seen in most double-blind, placebo controlled studies. The drugs that are effective for antihistamine-resistant chronic spontaneous urticaria are corticosteroids, cyclosporine, and Omalizumab. Use of steroids is limited by toxicity. If used at all, a dose of no more than 10 mg/day should be employed with a weekly reduction of 1 mg. The response rates to cyclosporine and Omalizumab are each close to 75%. Cyclosporine can be used effectively if care is taken to monitor blood pressure, urine protein, blood urea nitrogen, and creatinine, every 6 weeks. Omalizumab has the best profile in terms of efficacy/toxicity and, once approved by federal agencies for use in chronic spontaneous urticaria, a dramatic change in the treatment paradigm, whether associated with autoimmunity or not, is predicted. A phase 3 trial is currently in place. Refractoriness to both Omalizumab and cyclosporine is expected to be less than 5 percent of patients. Other agents, can then be tried." @default.
• W2126299285 created "2016-06-24" @default.
• W2126299285 creator A5053946031 @default.
• W2126299285 date "2012-01-01" @default.
• W2126299285 modified "2023-10-17" @default.
• W2126299285 title "Treatment of Chronic Spontaneous Urticaria" @default.
• W2126299285 cites W117176610 @default.
• W2126299285 cites W1946501151 @default.
• W2126299285 cites W1963859872 @default.
• W2126299285 cites W1964177914 @default.
• W2126299285 cites W1969177745 @default.
• W2126299285 cites W1976551703 @default.
• W2126299285 cites W1989548056 @default.
• W2126299285 cites W1991268557 @default.
• W2126299285 cites W1999304975 @default.
• W2126299285 cites W2000668449 @default.
• W2126299285 cites W2008522659 @default.
• W2126299285 cites W2015901270 @default.
• W2126299285 cites W2016186233 @default.
• W2126299285 cites W2022382470 @default.
• W2126299285 cites W2022878537 @default.
• W2126299285 cites W2024045584 @default.
• W2126299285 cites W2027234358 @default.
• W2126299285 cites W2029692925 @default.
• W2126299285 cites W2031640798 @default.
• W2126299285 cites W2032265228 @default.
• W2126299285 cites W2032558616 @default.
• W2126299285 cites W2036051127 @default.
• W2126299285 cites W2037765836 @default.
• W2126299285 cites W2038908978 @default.
• W2126299285 cites W2040067540 @default.
• W2126299285 cites W2040737274 @default.
• W2126299285 cites W2044022133 @default.
• W2126299285 cites W2053471993 @default.
• W2126299285 cites W2053770531 @default.
• W2126299285 cites W2057347176 @default.
• W2126299285 cites W2060105221 @default.
• W2126299285 cites W2063316222 @default.
• W2126299285 cites W2064949829 @default.
• W2126299285 cites W2068972960 @default.
• W2126299285 cites W2072607260 @default.
• W2126299285 cites W2073934357 @default.
• W2126299285 cites W2080768573 @default.
• W2126299285 cites W2083666610 @default.
• W2126299285 cites W2085255857 @default.
• W2126299285 cites W2090261265 @default.
• W2126299285 cites W2095572399 @default.
• W2126299285 cites W2107253938 @default.
• W2126299285 cites W2116150353 @default.
• W2126299285 cites W2118966064 @default.
• W2126299285 cites W2123921099 @default.
• W2126299285 cites W2132229178 @default.
• W2126299285 cites W2134459376 @default.
• W2126299285 cites W2136184915 @default.
• W2126299285 cites W2151154558 @default.
• W2126299285 cites W2155362172 @default.
• W2126299285 cites W2171083858 @default.
• W2126299285 cites W2766013461 @default.
• W2126299285 cites W4242194017 @default.
• W2126299285 doi "https://doi.org/10.4168/aair.2012.4.6.326" @default.
• W2126299285 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3479225" @default.
• W2126299285 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23115728" @default.
• W2126299285 hasPublicationYear "2012" @default.
• W2126299285 type Work @default.
• W2126299285 sameAs 2126299285 @default.
• W2126299285 citedByCount "84" @default.
• W2126299285 countsByYear W21262992852013 @default.
• W2126299285 countsByYear W21262992852014 @default.
• W2126299285 countsByYear W21262992852015 @default.
• W2126299285 countsByYear W21262992852016 @default.
• W2126299285 countsByYear W21262992852017 @default.
• W2126299285 countsByYear W21262992852018 @default.
• W2126299285 countsByYear W21262992852019 @default.
• W2126299285 countsByYear W21262992852020 @default.
• W2126299285 countsByYear W21262992852021 @default.
• W2126299285 countsByYear W21262992852022 @default.
• W2126299285 countsByYear W21262992852023 @default.
• W2126299285 crossrefType "journal-article" @default.
• W2126299285 hasAuthorship W2126299285A5053946031 @default.
• W2126299285 hasBestOaLocation W21262992852 @default.
• W2126299285 hasConcept C1122143 @default.
• W2126299285 hasConcept C126322002 @default.
• W2126299285 hasConcept C141105273 @default.
• W2126299285 hasConcept C142724271 @default.
• W2126299285 hasConcept C159654299 @default.
• W2126299285 hasConcept C203014093 @default.
• W2126299285 hasConcept C204787440 @default.
• W2126299285 hasConcept C27081682 @default.
• W2126299285 hasConcept C2776880894 @default.
• W2126299285 hasConcept C2778564945 @default.
• W2126299285 hasConcept C2779123688 @default.
• W2126299285 hasConcept C2779134260 @default.
• W2126299285 hasConcept C2779383735 @default.
• W2126299285 hasConcept C2780479503 @default.
• W2126299285 hasConcept C2781292560 @default.
• W2126299285 hasConcept C3008058167 @default.
• W2126299285 hasConcept C42219234 @default.
• W2126299285 hasConcept C524204448 @default.

• next